vs
Side-by-side financial comparison of Crexendo, Inc. (CXDO) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $18.1M, roughly 1.1× Crexendo, Inc.). Crexendo, Inc. runs the higher net margin — 6.7% vs -20.4%, a 27.2% gap on every dollar of revenue. On growth, Crexendo, Inc. posted the faster year-over-year revenue change (11.2% vs 6.9%). Over the past eight quarters, Crexendo, Inc.'s revenue compounded faster (12.4% CAGR vs 2.9%).
Crexendo, Inc. is a U.S.-headquartered cloud communications technology provider. It delivers unified communications as a service (UCaaS), contact center solutions, business VoIP services, and collaborative work tools, primarily catering to small and medium-sized enterprises operating in the North American market.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
CXDO vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.1M | $20.4M |
| Net Profit | $1.2M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | 6.3% | -18.0% |
| Net Margin | 6.7% | -20.4% |
| Revenue YoY | 11.2% | 6.9% |
| Net Profit YoY | 140.2% | 64.9% |
| EPS (diluted) | $0.03 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.1M | $20.4M | ||
| Q3 25 | $17.5M | $19.9M | ||
| Q2 25 | $16.6M | $19.6M | ||
| Q1 25 | $16.1M | $17.5M | ||
| Q4 24 | $16.2M | $19.1M | ||
| Q3 24 | $15.6M | $20.2M | ||
| Q2 24 | $14.7M | $21.4M | ||
| Q1 24 | $14.3M | $19.3M |
| Q4 25 | $1.2M | $-4.2M | ||
| Q3 25 | $1.4M | $-8.2M | ||
| Q2 25 | $1.2M | $-11.9M | ||
| Q1 25 | $1.2M | $-14.2M | ||
| Q4 24 | $507.0K | $-11.8M | ||
| Q3 24 | $148.0K | $-11.1M | ||
| Q2 24 | $588.0K | $-12.3M | ||
| Q1 24 | $434.0K | $-16.3M |
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | 6.3% | -18.0% | ||
| Q3 25 | 7.5% | -39.7% | ||
| Q2 25 | 6.7% | -59.6% | ||
| Q1 25 | 7.2% | -79.2% | ||
| Q4 24 | 3.9% | -62.5% | ||
| Q3 24 | 0.9% | -55.7% | ||
| Q2 24 | 3.9% | -59.2% | ||
| Q1 24 | 3.4% | -76.4% |
| Q4 25 | 6.7% | -20.4% | ||
| Q3 25 | 8.3% | -41.0% | ||
| Q2 25 | 7.4% | -61.0% | ||
| Q1 25 | 7.3% | -80.8% | ||
| Q4 24 | 3.1% | -62.1% | ||
| Q3 24 | 0.9% | -54.9% | ||
| Q2 24 | 4.0% | -57.7% | ||
| Q1 24 | 3.0% | -84.4% |
| Q4 25 | $0.03 | $-0.07 | ||
| Q3 25 | $0.05 | $-0.16 | ||
| Q2 25 | $0.04 | $-0.23 | ||
| Q1 25 | $0.04 | $-0.28 | ||
| Q4 24 | $0.03 | $-0.23 | ||
| Q3 24 | $0.00 | $-0.22 | ||
| Q2 24 | $0.02 | $-0.25 | ||
| Q1 24 | $0.01 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $92.0M |
| Total DebtLower is stronger | $114.0K | $42.4M |
| Stockholders' EquityBook value | $63.8M | $63.9M |
| Total Assets | $77.7M | $115.3M |
| Debt / EquityLower = less leverage | 0.00× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $92.0M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $101.5M | ||
| Q1 25 | — | $108.8M | ||
| Q4 24 | — | $120.4M | ||
| Q3 24 | — | $118.6M | ||
| Q2 24 | — | $118.2M | ||
| Q1 24 | — | $127.3M |
| Q4 25 | $114.0K | $42.4M | ||
| Q3 25 | $236.0K | $42.4M | ||
| Q2 25 | $356.0K | $42.4M | ||
| Q1 25 | $475.0K | $42.4M | ||
| Q4 24 | $592.0K | $40.0M | ||
| Q3 24 | $709.0K | $37.1M | ||
| Q2 24 | $823.0K | $35.0M | ||
| Q1 24 | $937.0K | $35.0M |
| Q4 25 | $63.8M | $63.9M | ||
| Q3 25 | $61.3M | $64.3M | ||
| Q2 25 | $58.3M | $70.0M | ||
| Q1 25 | $55.2M | $77.6M | ||
| Q4 24 | $51.4M | $87.5M | ||
| Q3 24 | $49.5M | $95.0M | ||
| Q2 24 | $48.2M | $101.6M | ||
| Q1 24 | $46.8M | $109.2M |
| Q4 25 | $77.7M | $115.3M | ||
| Q3 25 | $76.0M | $116.3M | ||
| Q2 25 | $71.4M | $122.0M | ||
| Q1 25 | $67.4M | $129.7M | ||
| Q4 24 | $64.9M | $142.8M | ||
| Q3 24 | $62.3M | $143.6M | ||
| Q2 24 | $59.6M | $149.7M | ||
| Q1 24 | $57.5M | $155.6M |
| Q4 25 | 0.00× | 0.66× | ||
| Q3 25 | 0.00× | 0.66× | ||
| Q2 25 | 0.01× | 0.61× | ||
| Q1 25 | 0.01× | 0.55× | ||
| Q4 24 | 0.01× | 0.46× | ||
| Q3 24 | 0.01× | 0.39× | ||
| Q2 24 | 0.02× | 0.34× | ||
| Q1 24 | 0.02× | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.3M | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | 0.0% | 0.8% |
| Cash ConversionOCF / Net Profit | 1.93× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.3M | $-1.8M | ||
| Q3 25 | $4.4M | $-8.7M | ||
| Q2 25 | $1.3M | $-7.5M | ||
| Q1 25 | $1.2M | $-11.6M | ||
| Q4 24 | $2.2M | $-3.5M | ||
| Q3 24 | $1.6M | $362.0K | ||
| Q2 24 | $2.7M | $-9.5M | ||
| Q1 24 | $-166.0K | $-9.8M |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | $1.3M | $-7.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.1M | $-3.6M | ||
| Q3 24 | — | $311.0K | ||
| Q2 24 | — | $-9.5M | ||
| Q1 24 | — | $-9.9M |
| Q4 25 | — | -9.7% | ||
| Q3 25 | — | -44.7% | ||
| Q2 25 | 7.7% | -39.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | 13.2% | -18.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | -44.7% | ||
| Q1 24 | — | -51.4% |
| Q4 25 | 0.0% | 0.8% | ||
| Q3 25 | 0.0% | 0.9% | ||
| Q2 25 | 0.1% | 1.1% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.2% | 0.7% | ||
| Q3 24 | 0.0% | 0.3% | ||
| Q2 24 | 0.0% | 0.4% | ||
| Q1 24 | 0.0% | 0.6% |
| Q4 25 | 1.93× | — | ||
| Q3 25 | 3.05× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 4.29× | — | ||
| Q3 24 | 10.95× | — | ||
| Q2 24 | 4.51× | — | ||
| Q1 24 | -0.38× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CXDO
| Services | $8.6M | 48% |
| Software Solution Segment | $8.3M | 46% |
| Products | $1.1M | 6% |
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
